# NCT03298087 (NCT03298087)

> Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: apalutamide plus abiraterone plus leuprolide
- Indication: newly diagnosed oligometastatic prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03298087
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: VA Office of Research and Development
- Conditions: Newly Diagnosed Oligometastatic Prostate Cancer
- Interventions: radical prostatectomy; stereotactic body radiotherapy; Leuprolide; apalutamide; abiraterone
- Enrollment: 28
- Primary outcome: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation)

## Indexed commentary on NCT03298087 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03298087